{"id":"azd3241","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297594","moleculeType":"Small molecule","molecularWeight":"253.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, AZD3241 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth.","oneSentence":"AZD3241 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:41.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT02388295","phase":"PHASE2","title":"AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-04-27","conditions":"Multiple System Atrophy, MSA","enrollment":59},{"nctId":"NCT01603069","phase":"PHASE2","title":"A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10","conditions":"Parkinson's Disease","enrollment":51},{"nctId":"NCT01527695","phase":"PHASE2","title":"PET Study in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Parkinson's Disease","enrollment":24},{"nctId":"NCT01457807","phase":"PHASE1","title":"To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Parkinson's Disease","enrollment":24},{"nctId":"NCT00914303","phase":"PHASE1","title":"Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Healthy","enrollment":77},{"nctId":"NCT00729443","phase":"PHASE1","title":"Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Healthy Volunteers","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD3241 to match placebo administered for 12 weeks."],"phase":"phase_2","status":"active","brandName":"AZD3241","genericName":"AZD3241","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD3241 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}